| 摘要 |
Provided are quinazolinone compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof:;
wherein R7, R8, and R9 are as defined herein. Methods of use, and pharmaceutical compositions of these compounds are also disclosed herein. |
| 主权项 |
1. A compound of formula (II):or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R7 is : halo; —(CH2)nOH; or (C1-C6)alkoyl, optionally substituted with one or more halo; or
—(CH2)nNHRd, wherein Rd is:
hydrogen;(C1-C6)alkyl, optionally substituted with one or more halo;—(CH2)n—(6 to 10 membered aryl);—C(O)—(CH2)n—(6 to 10 membered aryl) or —C(O)—(CH2)n—(6 to 10 membered heteroaryl), wherein the aryl or heteroaryl is optionally substituted with one or more of: halo; —SCF3; (C1-C6)alkyl, itself optionally substituted with one or more halo; or (C1-C6)alkoxy, itself optionally substituted with one or more halo;—C(O)—(C1-C8)alkyl, wherein the alkyl is optionally substituted with one or more halo;—C(O)—(CH2)n—(C3-C 10-cycloalkyl);—C(O)—(CH2)n—NReRf, wherein Re and Rf are each independently:
hydrogen;(C1-C6)alkyl, optionally substituted with one or more halo;(C1-C6)alkoxy, optionally substituted with one or more halo; or6 to 10 membered aryl, optionally substituted with one or more of:halo; (Ci-C6)alkyl, itself optionally substituted with one or more halo; or (C1-C6)alkoxy, itself optionally substituted with one or more halo;—C(O)—(CH2)n—(C1-C6)alkyl; or—C(O)—(CH2)n—(CH2)n-(6 to 10 membered aryl); R8 is: hydrogen; —(CH2)nOH; phenyl; —O—(Ci-C6)alkyl; or (C1-C6)alkyl, optionally substituted with one or more halo; R9 is: hydrogen; or (C1-C6)alkyl, optionally substituted with one or more halo; and n is 0, 1, or 2. |
